

TO WHOM IT MAY CONCERN

The undersigned, Gergely Tölgyesi PhD, Head of Assay R&D at Omixon Biocomputing Ltd, Budapest, Hungary, hereby declares that the following preparations

- Fragmentation Buffer (B) R21/R22
- Enhancer 1 E01
- Enhancer 2 E02
- HLA-A Primer Mix P013/P012
- HLA-B Primer Mix P023/P022
- HLA-C Primer Mix P033/P032
- HLA-DRB1 Primer Mix P042/043
- HLA-DRB1/DRB3 Primer Mix P42.1/P43.1
- HLA-DRB4 Primer Mix P102/P103
- HLA-DRB5 Primer Mix P112/113
- HLA-DQB1 set 1 Primer Mix P053/P052
- HLA-DQB1 set 2 Primer Mix P063/P062
- HLA-DQB1 set 3 Primer Mix P122/P123
- HLA-DPA1 Primer Mix P132/P133
- HLA-DPB1 Primer Mix P072/P073
- HLA-DPA1/B1 Primer Mix P092/P093

- HLA-DQA1 Primer Mix P083/P082
- Adaptor Plate A (i1-96) N1
- Adaptor Plate B (i97-192) N2
- Adaptor Plate C (i193-288) N3
- Adaptor Plate A1 (i1-24) N4
- Adaptor Plate A2 (i25-48) N7
- Adaptor Plate A3 (i49-72) N8
- Adaptor Plate A4 (i72-96) N9

sold by Omixon, do not contain dangerous substances, as defined in European Regulation (EC) No 1272/2008 on classification, labeling and packaging of substances and mixtures, at concentrations requiring the distribution of Safety Data Sheets as specified in the REACH regulation 1907/2006.

Therefore, Safety Data Sheets for these products have not been created.

2018/09/17

A handwritten signature in blue ink that reads "Gergely Tölgyesi".

(Signature)

Name: Gergely Tölgyesi, PhD
Function: Head of Assay R & D